Product on the market
CarciReagent® is a commercialised IVD medical device for self-testing with active D2C and distribution channels.
Company
An investment platform built for disciplined international growth
CNEU MEDICAL INVEST is developing an international platform around CNEU MEDICAL, CarciReagent®, regulatory infrastructure and distribution.
Investment thesis
Not a concept on paper. The next stage of an operating MedTech business.
The investor story is built around an existing product, rapid commercial growth, an international distribution pipeline and defined growth milestones.
Commercial momentum
Management reports revenue growth from CZK 2.064m in 2023 to CZK 48.946m in 2025.
International expansion
The distribution network and commercial pipeline span European and non-European markets at different stages of activation.
Further catalysts
IVDR, product-development completion and the planned veterinary platform create further potential milestones.
Business model
Multiple routes to market around one product core
CNEU MEDICAL is building a platform around CarciReagent® — a commercialised IVD self-test for home use — connecting product, regulatory know-how, D2C sales and international distribution.
Direct D2C sales
The owned e-commerce channel provides direct customer access and a fast way to test markets.
Wholesale
Scale through approved commercial partners and retail/distribution channels.
International distributors
Local partners support market entry and commercial execution.
Private investment opportunity
Want to review the numbers, round terms and investor documents?
Request individual investor access. Following manual review, approved investors may receive detailed materials and data-room access.
Public information is presented in line with available source materials. Forecasts are management estimates and future results are not guaranteed.